Migräne: neue Prophylaktika bei Non-Respondern
Die aktuelle Datenlage zu CGRP-Antikörpern, CGRP-Rezeptor-Antikörpern und Gepanten bei Migräne-Patienten, die nicht auf die üblichen Prophylaktika angesprochen haben, fasst ein Review zusammen. Fazit: Die neuen Prophylaktika können Non-Responder hoffen lassen.
Liebe Leserin, lieber Leser,
der Inhalt dieses Artikels ist nur für medizinische Fachkreise zugelassen. Wenn Sie zu diesen Fachkreisen gehören, melden Sie sich bitte auf unserer Seite an. Sie werden dann automatisch auf die gewünschte Seite weitergeleitet.
Quelle:
- Lee et al. (2023): New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy. Cephalalgia, DOI: https://doi.org/10.1177/03331024221146315
- Reuter et al. (2018): Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. The Lancet, DOI: https://doi.org/10.1016/S0140-6736(18)32534-0
- Ferrari et al. (2019): Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. The Lancet, DOI: https://doi.org/10.1016/S0140-6736(19)31946-4
- Mulleners et al. (2020): Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. The Lancet Neurology, DOI: https://doi.org/10.1016/S1474-4422(20)30279-9
- Ashina et al. (2022): Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. The Lancet Neurology, DOI: https://doi.org/10.1016/S1474-4422(22)00185-5
- Barbanti et al. (2022): Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). The Journal of Headache and Pain, DOI: https://doi.org/10.1186/s10194-022-01396-x
- Vernieri et al. (2021): Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). The Journal of Headache and Pain, DOI: https://doi.org/10.1186/s10194-021-01247-1
- Croop et al. (2021): Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. The Lancet, DOI: https://doi.org/10.1016/S0140-6736(20)32544-7
- Overeem et al. (2021): Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study. Cephalalgia, DOI: https://doi.org/10.1177/03331024211048
Neurologie
Neurologische Erkrankungen
Neurologie-Kongresse
Gelbe Liste Campus: CME für Ärzte
Newsletter
